Incubate has urged Congress to take action and ensure the 2025 Special 301 Report reaffirms America’s commitment to safeguarding innovation.
Strong intellectual property (IP) protections are the backbone of American innovation, particularly in the biopharmaceutical industry, where startups rely on secure patents to attract investment and develop life-saving treatments. For decades, the Special 301 Report has been a key tool in identifying and pressuring foreign governments that fail to uphold IP rights, ensuring that U.S. businesses and researchers remain competitive on a global scale. However, in recent years, this critical report has softened its stance, failing to call out major offenders and dangerous policies like compulsory licensing—where foreign governments allow domestic companies to infringe on American patents without consequences. Without stronger enforcement, biotech innovation risks slowing down, limiting future medical breakthroughs and economic growth.
Incubate has urged Congress to take action and ensure the 2025 Special 301 Report reaffirms America’s commitment to safeguarding innovation. Read our full letters to the Senate and House to learn why this issue is more urgent than ever.
Comments